Modality
mRNA
MOA
BTKi
Target
BET
Pathway
NF-κB
HCC
Development Pipeline
Preclinical
~Jan 2022
→ ~Apr 2023
Phase 1
Jul 2023
→ Oct 2030
Phase 1Current
NCT03193520
1,923 pts·HCC
2025-07→2028-08·Not yet recruiting
NCT05508850
718 pts·HCC
2023-07→2030-10·Not yet recruiting
2,641 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-08-232.4y awayPh2 Data· HCC
2030-10-284.6y awayPh2 Data· HCC
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2028-08-23 · 2.4y away
HCC
Ph2 Data
2030-10-28 · 4.6y away
HCC
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03193520 | Phase 1/2 | HCC | Not yet recr... | 1923 | PFS |
| NCT05508850 | Phase 1/2 | HCC | Not yet recr... | 718 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 |